Cynvenio is the pioneer in LiquidBiopsy® technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine strategies.
Cynvenio is dedicated to developing tools to enable the early detection, longitudinal monitoring and targeted treatment of cancer.
ClearID® liquid biopsy testing by Cynvenio provides physicians with real-time, actionable insights to support personalized treatment paths.
The LiquidBiopsy® platform enables the isolation, enumeration, and molecular analysis of rare cells and cell-free DNA from whole-blood samples.
